Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis

The purpose of this study was to determine the cumulative incidence of lupus nephritis (LN) and the factors predictive of its occurrencein a multiethnic systemic lupus erythematosus (SLE) cohort. We studied 353 SLE patients as de” ned by the American College of Rheumatology (ACR) criteria (65 Hispan...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lupus 2002-01, Vol.11 (3), p.152-160
Hauptverfasser: Bastian, H M, Roseman, J M, Mcgwin, G, Alarcón, G S, Friedman, A W, Fessler, B J, Baethge, B A, Reveille, J D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 160
container_issue 3
container_start_page 152
container_title Lupus
container_volume 11
creator Bastian, H M
Roseman, J M
Mcgwin, G
Alarcón, G S
Friedman, A W
Fessler, B J
Baethge, B A
Reveille, J D
description The purpose of this study was to determine the cumulative incidence of lupus nephritis (LN) and the factors predictive of its occurrencein a multiethnic systemic lupus erythematosus (SLE) cohort. We studied 353 SLE patients as de” ned by the American College of Rheumatology (ACR) criteria (65 Hispanics, 93 African-Americans and 91 Caucasians). First, we determined the cumulative incidence of LN in all patients. Next, we determined the predictors for LN in those with nephritis occurring after diagnosis. The dependent variable, LN, was de” ned by: (1) A renal biopsy demonstrating World Health Organization (WHO), class II–V histopathology; and/or (2) proteinuria≥ 0.5 g=24 h or 3 + proteinuria attributable to SLE; and/or (3) one of the following features also attributable to SLE and present on two or more visits, which were performed at least 6 months apart— proteinuria≥ 2 +, serum creatinine≥ 1.4 mg/dl, creatinine clearance ≤ 79 ml/min, 10 RBCs or WBCs per high power ” eld (hpf), oŗ 3 granular or cellular casts per hpf. Independent variables assessed at diagnosis, and if absent, at baseline, were from four domains: sociodemographic, clinical, immunologic and immunogenetic (including the complete antibody pro” le and MHC class II alleles), and health habits. Variables with P < 0.05 by chi square analyses were entered into domain-speci”c stepwise logistic regression analyses controlling for disease duration, with LN as the dependent variable. Signi” cant domain-speci”c regression variables (P ≤ 0.1) were then entered into an overall model. The cumulative incidence of LN was 54.3% in all patients, and 35.3% for those developing LN after diagnosis. LN after diagnosis occurred in 43.1% of 65 Hispanics, 50.5% of 93 African-Americans, and 14.3% of 91 Caucasians, P < 0.0001. The duration of follow-up for those with LN after diagnosis was 5.5§ 2.4 vs 4.0§ 2.9 years for those without LN. Hispanic (odds ratio (OR) = 2.71, 95% con” dence limits (CL) = 1.07–6.87, P < 0.04) and African-American ethnicities (OR = 3.13, 95% CL = 1.21–8.09, P < 0.02), not married or living together (OR = 3.45, 95% CL = 1.69–7.69, P < 0.0003), higher SLAM score (OR = 1.11, 95% CL = 1.02–1.19, P < 0.007), anti-dsDNA (OR = 3.14, 95% CL = 1.50–6.57, P < 0.0001) and anti-RNP (OR = 4.24, CL = 1.98–9.07, P < 0.0001) antibodies were shown to be signi” cant predictors of the occurrence of LN. Repeated analyses excluding the patients with missing HLA data showed that absence of HLA-DQB1*0201 was also a
doi_str_mv 10.1191/0961203302lu158oa
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71698340</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1191_0961203302lu158oa</sage_id><sourcerecordid>71698340</sourcerecordid><originalsourceid>FETCH-LOGICAL-c460t-45706ac0712d4eee87daca93983a726d1565da06a764067fb6b3c1c9d7f99fab3</originalsourceid><addsrcrecordid>eNqFkV1LwzAUhoMoOqc_wBsJXnjXmbRd0lyK-DEQBD_Au5Klp1tm29Sc9GL_3owNBEW8OoTzvM8hvISccTbhXPErpgRPWZaxtBn4tHB6j4x4LmUSF-k-GW32yQY4IseIK8ZYxpU4JEcxxXJZFCOyelljgNYa2gz9gBT8Oiyh1cFhfNmOhqUHoBCWXWQW3g09Tuj7bDahzxY_aK1NcB5p7fzO0EG_9DZYpLoO4Gll9aJzaPGEHNS6QTjdzTF5u7t9vXlIHp_uZzfXj4nJBQtJPpVMaMMkT6scAApZaaNVpopMy1RUfCqmlY6IFDkTsp6LeWa4UZWslar1PBuTy6239-5zAAxla9FA0-gO3ICl5CK6cvYvyItM5YptwIsf4MoNvoufKNM0FSJ2ISPEt5DxDtFDXfbettqvS87KTV3lr7pi5nwnHuYtVN-JXT8RmGwB1Av4vvq38Qsnl5-t</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222661917</pqid></control><display><type>article</type><title>Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis</title><source>SAGE Complete A-Z List</source><source>MEDLINE</source><creator>Bastian, H M ; Roseman, J M ; Mcgwin, G ; Alarcón, G S ; Friedman, A W ; Fessler, B J ; Baethge, B A ; Reveille, J D</creator><creatorcontrib>Bastian, H M ; Roseman, J M ; Mcgwin, G ; Alarcón, G S ; Friedman, A W ; Fessler, B J ; Baethge, B A ; Reveille, J D ; LUMINA Study Group. LUpus in MInority populations: NAture vs nurture ; Lumina Study Group</creatorcontrib><description><![CDATA[The purpose of this study was to determine the cumulative incidence of lupus nephritis (LN) and the factors predictive of its occurrencein a multiethnic systemic lupus erythematosus (SLE) cohort. We studied 353 SLE patients as de” ned by the American College of Rheumatology (ACR) criteria (65 Hispanics, 93 African-Americans and 91 Caucasians). First, we determined the cumulative incidence of LN in all patients. Next, we determined the predictors for LN in those with nephritis occurring after diagnosis. The dependent variable, LN, was de” ned by: (1) A renal biopsy demonstrating World Health Organization (WHO), class II–V histopathology; and/or (2) proteinuria≥ 0.5 g=24 h or 3 + proteinuria attributable to SLE; and/or (3) one of the following features also attributable to SLE and present on two or more visits, which were performed at least 6 months apart— proteinuria≥ 2 +, serum creatinine≥ 1.4 mg/dl, creatinine clearance ≤ 79 ml/min, 10 RBCs or WBCs per high power ” eld (hpf), oŗ 3 granular or cellular casts per hpf. Independent variables assessed at diagnosis, and if absent, at baseline, were from four domains: sociodemographic, clinical, immunologic and immunogenetic (including the complete antibody pro” le and MHC class II alleles), and health habits. Variables with P < 0.05 by chi square analyses were entered into domain-speci”c stepwise logistic regression analyses controlling for disease duration, with LN as the dependent variable. Signi” cant domain-speci”c regression variables (P ≤ 0.1) were then entered into an overall model. The cumulative incidence of LN was 54.3% in all patients, and 35.3% for those developing LN after diagnosis. LN after diagnosis occurred in 43.1% of 65 Hispanics, 50.5% of 93 African-Americans, and 14.3% of 91 Caucasians, P < 0.0001. The duration of follow-up for those with LN after diagnosis was 5.5§ 2.4 vs 4.0§ 2.9 years for those without LN. Hispanic (odds ratio (OR) = 2.71, 95% con” dence limits (CL) = 1.07–6.87, P < 0.04) and African-American ethnicities (OR = 3.13, 95% CL = 1.21–8.09, P < 0.02), not married or living together (OR = 3.45, 95% CL = 1.69–7.69, P < 0.0003), higher SLAM score (OR = 1.11, 95% CL = 1.02–1.19, P < 0.007), anti-dsDNA (OR = 3.14, 95% CL = 1.50–6.57, P < 0.0001) and anti-RNP (OR = 4.24, CL = 1.98–9.07, P < 0.0001) antibodies were shown to be signi” cant predictors of the occurrence of LN. Repeated analyses excluding the patients with missing HLA data showed that absence of HLA-DQB1*0201 was also a signi” cant predictor for the occurrence of LN (OR = 2.34, CL = 1.13–5.26, P < 0.04). In conclusion, LN occurred signi” cantly more often in Hispanics and African-Americans with SLE. Sociodemographic,clinical and immunologic/immunogenetic factors seem to be predictive of LN occurring after the diagnosis of SLE has been made.]]></description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1191/0961203302lu158oa</identifier><identifier>PMID: 12004788</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>African Americans ; Autoantibodies - immunology ; Cohort Studies ; Creatinine ; Ethnic Groups ; Ethnicity ; European Continental Ancestry Group ; Female ; Hispanic Americans ; HLA-D Antigens - immunology ; Humans ; Logistic Models ; Lupus ; Lupus Erythematosus, Systemic - complications ; Lupus Erythematosus, Systemic - diagnosis ; Lupus Nephritis - complications ; Lupus Nephritis - epidemiology ; Lupus Nephritis - ethnology ; Lupus Nephritis - immunology ; Male ; Medicine ; Minority &amp; ethnic groups ; Mortality ; Odds Ratio ; Rheumatology ; Risk Factors ; Sociodemographics ; Survival Analysis ; Variables ; White people</subject><ispartof>Lupus, 2002-01, Vol.11 (3), p.152-160</ispartof><rights>2002 Arnold</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c460t-45706ac0712d4eee87daca93983a726d1565da06a764067fb6b3c1c9d7f99fab3</citedby><cites>FETCH-LOGICAL-c460t-45706ac0712d4eee87daca93983a726d1565da06a764067fb6b3c1c9d7f99fab3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1191/0961203302lu158oa$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1191/0961203302lu158oa$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12004788$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bastian, H M</creatorcontrib><creatorcontrib>Roseman, J M</creatorcontrib><creatorcontrib>Mcgwin, G</creatorcontrib><creatorcontrib>Alarcón, G S</creatorcontrib><creatorcontrib>Friedman, A W</creatorcontrib><creatorcontrib>Fessler, B J</creatorcontrib><creatorcontrib>Baethge, B A</creatorcontrib><creatorcontrib>Reveille, J D</creatorcontrib><creatorcontrib>LUMINA Study Group. LUpus in MInority populations: NAture vs nurture</creatorcontrib><creatorcontrib>Lumina Study Group</creatorcontrib><title>Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis</title><title>Lupus</title><addtitle>Lupus</addtitle><description><![CDATA[The purpose of this study was to determine the cumulative incidence of lupus nephritis (LN) and the factors predictive of its occurrencein a multiethnic systemic lupus erythematosus (SLE) cohort. We studied 353 SLE patients as de” ned by the American College of Rheumatology (ACR) criteria (65 Hispanics, 93 African-Americans and 91 Caucasians). First, we determined the cumulative incidence of LN in all patients. Next, we determined the predictors for LN in those with nephritis occurring after diagnosis. The dependent variable, LN, was de” ned by: (1) A renal biopsy demonstrating World Health Organization (WHO), class II–V histopathology; and/or (2) proteinuria≥ 0.5 g=24 h or 3 + proteinuria attributable to SLE; and/or (3) one of the following features also attributable to SLE and present on two or more visits, which were performed at least 6 months apart— proteinuria≥ 2 +, serum creatinine≥ 1.4 mg/dl, creatinine clearance ≤ 79 ml/min, 10 RBCs or WBCs per high power ” eld (hpf), oŗ 3 granular or cellular casts per hpf. Independent variables assessed at diagnosis, and if absent, at baseline, were from four domains: sociodemographic, clinical, immunologic and immunogenetic (including the complete antibody pro” le and MHC class II alleles), and health habits. Variables with P < 0.05 by chi square analyses were entered into domain-speci”c stepwise logistic regression analyses controlling for disease duration, with LN as the dependent variable. Signi” cant domain-speci”c regression variables (P ≤ 0.1) were then entered into an overall model. The cumulative incidence of LN was 54.3% in all patients, and 35.3% for those developing LN after diagnosis. LN after diagnosis occurred in 43.1% of 65 Hispanics, 50.5% of 93 African-Americans, and 14.3% of 91 Caucasians, P < 0.0001. The duration of follow-up for those with LN after diagnosis was 5.5§ 2.4 vs 4.0§ 2.9 years for those without LN. Hispanic (odds ratio (OR) = 2.71, 95% con” dence limits (CL) = 1.07–6.87, P < 0.04) and African-American ethnicities (OR = 3.13, 95% CL = 1.21–8.09, P < 0.02), not married or living together (OR = 3.45, 95% CL = 1.69–7.69, P < 0.0003), higher SLAM score (OR = 1.11, 95% CL = 1.02–1.19, P < 0.007), anti-dsDNA (OR = 3.14, 95% CL = 1.50–6.57, P < 0.0001) and anti-RNP (OR = 4.24, CL = 1.98–9.07, P < 0.0001) antibodies were shown to be signi” cant predictors of the occurrence of LN. Repeated analyses excluding the patients with missing HLA data showed that absence of HLA-DQB1*0201 was also a signi” cant predictor for the occurrence of LN (OR = 2.34, CL = 1.13–5.26, P < 0.04). In conclusion, LN occurred signi” cantly more often in Hispanics and African-Americans with SLE. Sociodemographic,clinical and immunologic/immunogenetic factors seem to be predictive of LN occurring after the diagnosis of SLE has been made.]]></description><subject>African Americans</subject><subject>Autoantibodies - immunology</subject><subject>Cohort Studies</subject><subject>Creatinine</subject><subject>Ethnic Groups</subject><subject>Ethnicity</subject><subject>European Continental Ancestry Group</subject><subject>Female</subject><subject>Hispanic Americans</subject><subject>HLA-D Antigens - immunology</subject><subject>Humans</subject><subject>Logistic Models</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - complications</subject><subject>Lupus Erythematosus, Systemic - diagnosis</subject><subject>Lupus Nephritis - complications</subject><subject>Lupus Nephritis - epidemiology</subject><subject>Lupus Nephritis - ethnology</subject><subject>Lupus Nephritis - immunology</subject><subject>Male</subject><subject>Medicine</subject><subject>Minority &amp; ethnic groups</subject><subject>Mortality</subject><subject>Odds Ratio</subject><subject>Rheumatology</subject><subject>Risk Factors</subject><subject>Sociodemographics</subject><subject>Survival Analysis</subject><subject>Variables</subject><subject>White people</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkV1LwzAUhoMoOqc_wBsJXnjXmbRd0lyK-DEQBD_Au5Klp1tm29Sc9GL_3owNBEW8OoTzvM8hvISccTbhXPErpgRPWZaxtBn4tHB6j4x4LmUSF-k-GW32yQY4IseIK8ZYxpU4JEcxxXJZFCOyelljgNYa2gz9gBT8Oiyh1cFhfNmOhqUHoBCWXWQW3g09Tuj7bDahzxY_aK1NcB5p7fzO0EG_9DZYpLoO4Gll9aJzaPGEHNS6QTjdzTF5u7t9vXlIHp_uZzfXj4nJBQtJPpVMaMMkT6scAApZaaNVpopMy1RUfCqmlY6IFDkTsp6LeWa4UZWslar1PBuTy6239-5zAAxla9FA0-gO3ICl5CK6cvYvyItM5YptwIsf4MoNvoufKNM0FSJ2ISPEt5DxDtFDXfbettqvS87KTV3lr7pi5nwnHuYtVN-JXT8RmGwB1Av4vvq38Qsnl5-t</recordid><startdate>20020101</startdate><enddate>20020101</enddate><creator>Bastian, H M</creator><creator>Roseman, J M</creator><creator>Mcgwin, G</creator><creator>Alarcón, G S</creator><creator>Friedman, A W</creator><creator>Fessler, B J</creator><creator>Baethge, B A</creator><creator>Reveille, J D</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20020101</creationdate><title>Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis</title><author>Bastian, H M ; Roseman, J M ; Mcgwin, G ; Alarcón, G S ; Friedman, A W ; Fessler, B J ; Baethge, B A ; Reveille, J D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c460t-45706ac0712d4eee87daca93983a726d1565da06a764067fb6b3c1c9d7f99fab3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>African Americans</topic><topic>Autoantibodies - immunology</topic><topic>Cohort Studies</topic><topic>Creatinine</topic><topic>Ethnic Groups</topic><topic>Ethnicity</topic><topic>European Continental Ancestry Group</topic><topic>Female</topic><topic>Hispanic Americans</topic><topic>HLA-D Antigens - immunology</topic><topic>Humans</topic><topic>Logistic Models</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - complications</topic><topic>Lupus Erythematosus, Systemic - diagnosis</topic><topic>Lupus Nephritis - complications</topic><topic>Lupus Nephritis - epidemiology</topic><topic>Lupus Nephritis - ethnology</topic><topic>Lupus Nephritis - immunology</topic><topic>Male</topic><topic>Medicine</topic><topic>Minority &amp; ethnic groups</topic><topic>Mortality</topic><topic>Odds Ratio</topic><topic>Rheumatology</topic><topic>Risk Factors</topic><topic>Sociodemographics</topic><topic>Survival Analysis</topic><topic>Variables</topic><topic>White people</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bastian, H M</creatorcontrib><creatorcontrib>Roseman, J M</creatorcontrib><creatorcontrib>Mcgwin, G</creatorcontrib><creatorcontrib>Alarcón, G S</creatorcontrib><creatorcontrib>Friedman, A W</creatorcontrib><creatorcontrib>Fessler, B J</creatorcontrib><creatorcontrib>Baethge, B A</creatorcontrib><creatorcontrib>Reveille, J D</creatorcontrib><creatorcontrib>LUMINA Study Group. LUpus in MInority populations: NAture vs nurture</creatorcontrib><creatorcontrib>Lumina Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bastian, H M</au><au>Roseman, J M</au><au>Mcgwin, G</au><au>Alarcón, G S</au><au>Friedman, A W</au><au>Fessler, B J</au><au>Baethge, B A</au><au>Reveille, J D</au><aucorp>LUMINA Study Group. LUpus in MInority populations: NAture vs nurture</aucorp><aucorp>Lumina Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2002-01-01</date><risdate>2002</risdate><volume>11</volume><issue>3</issue><spage>152</spage><epage>160</epage><pages>152-160</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract><![CDATA[The purpose of this study was to determine the cumulative incidence of lupus nephritis (LN) and the factors predictive of its occurrencein a multiethnic systemic lupus erythematosus (SLE) cohort. We studied 353 SLE patients as de” ned by the American College of Rheumatology (ACR) criteria (65 Hispanics, 93 African-Americans and 91 Caucasians). First, we determined the cumulative incidence of LN in all patients. Next, we determined the predictors for LN in those with nephritis occurring after diagnosis. The dependent variable, LN, was de” ned by: (1) A renal biopsy demonstrating World Health Organization (WHO), class II–V histopathology; and/or (2) proteinuria≥ 0.5 g=24 h or 3 + proteinuria attributable to SLE; and/or (3) one of the following features also attributable to SLE and present on two or more visits, which were performed at least 6 months apart— proteinuria≥ 2 +, serum creatinine≥ 1.4 mg/dl, creatinine clearance ≤ 79 ml/min, 10 RBCs or WBCs per high power ” eld (hpf), oŗ 3 granular or cellular casts per hpf. Independent variables assessed at diagnosis, and if absent, at baseline, were from four domains: sociodemographic, clinical, immunologic and immunogenetic (including the complete antibody pro” le and MHC class II alleles), and health habits. Variables with P < 0.05 by chi square analyses were entered into domain-speci”c stepwise logistic regression analyses controlling for disease duration, with LN as the dependent variable. Signi” cant domain-speci”c regression variables (P ≤ 0.1) were then entered into an overall model. The cumulative incidence of LN was 54.3% in all patients, and 35.3% for those developing LN after diagnosis. LN after diagnosis occurred in 43.1% of 65 Hispanics, 50.5% of 93 African-Americans, and 14.3% of 91 Caucasians, P < 0.0001. The duration of follow-up for those with LN after diagnosis was 5.5§ 2.4 vs 4.0§ 2.9 years for those without LN. Hispanic (odds ratio (OR) = 2.71, 95% con” dence limits (CL) = 1.07–6.87, P < 0.04) and African-American ethnicities (OR = 3.13, 95% CL = 1.21–8.09, P < 0.02), not married or living together (OR = 3.45, 95% CL = 1.69–7.69, P < 0.0003), higher SLAM score (OR = 1.11, 95% CL = 1.02–1.19, P < 0.007), anti-dsDNA (OR = 3.14, 95% CL = 1.50–6.57, P < 0.0001) and anti-RNP (OR = 4.24, CL = 1.98–9.07, P < 0.0001) antibodies were shown to be signi” cant predictors of the occurrence of LN. Repeated analyses excluding the patients with missing HLA data showed that absence of HLA-DQB1*0201 was also a signi” cant predictor for the occurrence of LN (OR = 2.34, CL = 1.13–5.26, P < 0.04). In conclusion, LN occurred signi” cantly more often in Hispanics and African-Americans with SLE. Sociodemographic,clinical and immunologic/immunogenetic factors seem to be predictive of LN occurring after the diagnosis of SLE has been made.]]></abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>12004788</pmid><doi>10.1191/0961203302lu158oa</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0961-2033
ispartof Lupus, 2002-01, Vol.11 (3), p.152-160
issn 0961-2033
1477-0962
language eng
recordid cdi_proquest_miscellaneous_71698340
source SAGE Complete A-Z List; MEDLINE
subjects African Americans
Autoantibodies - immunology
Cohort Studies
Creatinine
Ethnic Groups
Ethnicity
European Continental Ancestry Group
Female
Hispanic Americans
HLA-D Antigens - immunology
Humans
Logistic Models
Lupus
Lupus Erythematosus, Systemic - complications
Lupus Erythematosus, Systemic - diagnosis
Lupus Nephritis - complications
Lupus Nephritis - epidemiology
Lupus Nephritis - ethnology
Lupus Nephritis - immunology
Male
Medicine
Minority & ethnic groups
Mortality
Odds Ratio
Rheumatology
Risk Factors
Sociodemographics
Survival Analysis
Variables
White people
title Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T18%3A35%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20lupus%20erythematosus%20in%20three%20ethnic%20groups.%20XII.%20Risk%20factors%20for%20lupus%20nephritis%20after%20diagnosis&rft.jtitle=Lupus&rft.au=Bastian,%20H%20M&rft.aucorp=LUMINA%20Study%20Group.%20LUpus%20in%20MInority%20populations:%20NAture%20vs%20nurture&rft.date=2002-01-01&rft.volume=11&rft.issue=3&rft.spage=152&rft.epage=160&rft.pages=152-160&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1191/0961203302lu158oa&rft_dat=%3Cproquest_cross%3E71698340%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222661917&rft_id=info:pmid/12004788&rft_sage_id=10.1191_0961203302lu158oa&rfr_iscdi=true